GVHD in animal models induces severe thymic atrophy as a result of prolonged secretion of high concentrations of adrenal glucocorticoids. In this study we investigated the mechanism responsible for the persistent stimulation of the adrenal glands to secrete glucocorticoids in mice undergoing GVHD. GVHD was induced across the major and multiple minor histocompatibility antigen difference in unirradiated C57Bl/6 x AF1 hybrid mice by the intravenous injection of A strain parental lymphoid cells. Our results showed plasma corticosterone (CS) levels were elevated in association with high concentrations of corticotropin (ACTH) in both the GVHD and control syngeneic (SYN) groups on day 9. By days 16 and 24, plasma CS and ACTH in the SYN mice returned to basal levels. In contrast, plasma CS levels remained elevated in the GVHD animals on days 16 and 24 despite decreasing concentrations of plasma ACTH. Reverse transcription-polymerase chain reaction (RT-PCR) showed several-fold increase in POMC mRNA in the adrenal glands of GVHD mice compared with SYN animals. In addition, high mRNA levels for murine prohormone convertase 1, the enzyme that cleaves POMC into ACTH, were also detected in GVHD adrenals. Histological analysis of GVHD adrenals failed to show any sign of adrenalitis, and RT-PCR of GVHD adrenals also failed to detect mRNA for interferon-gamma (IFN-gamma), a cytokine expressed by activated T and natural killer (NK) cells. However, mRNA for IL-12, a cytokine produced by activated macrophages, was increased in GVHD adrenals, suggesting that resident adrenal macrophages were activated during GVHD. Our findings suggest that persistent elevated levels of plasma glucocorticoids during GVHD could be mediated by intra-adrenal ACTH produced by resident adrenal macrophages activated as a consequence of GVHD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553375PMC
http://dx.doi.org/10.1111/j.1365-2249.1995.tb03858.xDOI Listing

Publication Analysis

Top Keywords

gvhd adrenals
16
gvhd
14
adrenal glands
12
pomc mrna
8
mrna adrenal
8
mice undergoing
8
persistent elevated
8
plasma corticosterone
8
corticosterone levels
8
high concentrations
8

Similar Publications

Article Synopsis
  • * Researchers analyzed data from 450 patients, finding that 310 were classified as ultra-low risk (ULR) based on their rapid clinical response and low MAP scores, leading to significantly better outcomes.
  • * Patients in the ULR group had higher response rates at day 28 and lower non-relapse mortality at six months, suggesting that careful monitoring can guide safer, more effective GVHD treatment strategies.
View Article and Find Full Text PDF

Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review.

Transpl Immunol

December 2024

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA. Electronic address:

Article Synopsis
  • Idiopathic Pneumonia Syndrome (IPS) is a serious complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT), potentially leading to high morbidity and mortality, often due to inflammatory damage.
  • This study examines the use of Ruxolitinib, a JAK inhibitor, combined with corticosteroids (CS) in treating IPS compared to standard corticosteroid treatment, through a case series of three patients and a systematic review of previous literature involving 346 cases.
  • Results indicated that the three patients treated with Ruxolitinib and CS showed significant improvement without mortality linked to IPS, and the systematic review supported these findings across a diverse patient demographic.
View Article and Find Full Text PDF

Background: Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie, <18 years) with moderate-to-severe chronic GVHD.

Methods: In this single-arm, phase 2 study, patients were recruited at 21 hospitals or clinics across 14 countries in Asia, Europe, and Canada.

View Article and Find Full Text PDF

Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). For many years, corticosteroids have been the mainstay treatment for GVHD, but cases of steroid-refractory GVHD and the severe adverse effects of high-dose corticosteroids have increased the need for preventative and therapeutic strategies for GVHD. Due to the nature of alloreactive T cells, GVHD is inherently linked to the graft-versus-leukemia (GVL) effect, the therapeutic driving force behind stem cell transplantation.

View Article and Find Full Text PDF

Corticosteroid treatment (CST) failure is associated with poor outcomes for patients with gastrointestinal (GI) graft-versus-host disease (GVHD). CST is intended to target the immune system, but the glucocorticoid receptor (GR) is widely expressed, including within the intestines, where its effects are poorly understood. Here, we report that corticosteroids (CS) directly targeted intestinal epithelium, potentially worsening immune-mediated GI damage.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!